---
document_datetime: 2023-09-21 19:57:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/azacitidine-mylan-epar-all-authorised-presentations_en.pdf
document_name: azacitidine-mylan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7904199
conversion_datetime: 2025-12-17 09:27:20.725816
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                 | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|-------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/20/1426/001 | Azacitidine Mylan | 25 mg/ml   | Powder for suspension for injection | Subcutaneous use          | vial (glass)          | 100 mg                    | 1 vial      |
| EU/1/20/1426/002 | Azacitidine Mylan | 25 mg/ml   | Powder for suspension for injection | Subcutaneous use          | vial (glass)          | 100 mg                    | 7 vials     |